Paraoxonase‐1 (PON1) Status Analysis Using Non‐Organophosphate Substrates
Open Access
- 1 January 2021
- journal article
- research article
- Published by Wiley in Current Protocols
- Vol. 1 (1) , e25
Abstract
Human paraoxonase‐1 (PON1) is a high‐density lipoprotein‐associated enzyme with antioxidant, anti‐inflammatory, and antiapoptotic roles. The ability of PON1 to hydrolyze specific organophosphate (OP) compounds and prevent accumulation of oxidized lipids in lipoproteins has prompted a large number of studies investigating PON1's role in modulating toxicity and disease. Most of these studies, however, have only focused on PON1 single nucleotide polymorphism analyses and have ignored PON1 activity levels, arguably the most important parameter in determining protection against exposure and disease. We developed a two‐substrate activity assay termed “PON1 status” that reveals both the functional PON1192 genotype and plasma PON1 activity levels. While our previous studies with PON1 status demonstrated that both PON1192 functional genotype and enzymatic activity levels obtained exclusively by determining PON1 status are required for a proper evaluation of PON1's role in modulating OP exposures and risk of disease, the original PON1 status assay requires the use of highly toxic OP metabolites. As many laboratories are not prepared to handle such toxic compounds and the associated waste generated, determination of PON1 status has been limited to rather few studies. Here, we describe a PON1 status protocol that uses non‐OP substrates with a resolution equivalent to that of the original PON1 status approach. We have also included useful suggestions to ensure the assays can easily be carried out in any laboratory. The protocols described here will enable a proper examination of the risk of exposure or susceptibility to disease in PON1 epidemiological studies without the need to handle highly toxic substrates. © 2021 Wiley Periodicals LLC.This article was corrected on 18 July 2022. See the end of the full text for details.Basic Protocol: Determining PON1 status using non‐organophosphate substratesSupport Protocol 1: Experimental pathlength determinationSupport Protocol 2: PON1 DNA genotyping for the Q192R (rs662) polymorphismKeywords
Funding Information
- National Science Foundation (R01 ES009883, P42 ES004696, P30 ES007033)
This publication has 64 references indexed in Scilit:
- Long term stability of paraoxonase-1 and high-density lipoprotein in human serumLipids in Health and Disease, 2012
- Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery diseaseJournal of Clinical Investigation, 2011
- Buffy coat specimens remain viable as a DNA source for highly multiplexed genome-wide genetic tests after long term storageJournal of Translational Medicine, 2011
- Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: The hunt goes onBiochemical Pharmacology, 2011
- Human PON1, a biomarker of risk of disease and exposureChemico-Biological Interactions, 2010
- Serum Cholinesterase Inhibition in Relation to Paraoxonase-1 (PON1) Status among Organophosphate-Exposed Agricultural Pesticide HandlersEnvironmental Health Perspectives, 2009
- Racial Differences in Paraoxonase-1 (PON1): A Factor in the Health of Southerners?Environmental Health Perspectives, 2009
- Validation of PON1 enzyme activity assays for longitudinal studiesClinica Chimica Acta, 2009
- Paraoxonase 1 (PON1) status and substrate hydrolysisToxicology and Applied Pharmacology, 2009
- Determination of Paraoxonase 1 Status Without the Use of Toxic Organophosphate SubstratesCirculation: Cardiovascular Genetics, 2008